Osteoporosis in practice. Katie Moss Rheumatology Consultant St George s Hospital London
|
|
- Theresa Jocelin McLaughlin
- 6 years ago
- Views:
Transcription
1 Osteoporosis in practice Katie Moss Rheumatology Consultant St George s Hospital London
2 Disclosures Lilly Educational grant and advisory board Prostrakan Educational grant
3 Osteoporosis Case history 66 year old women Presents with new thoracic back pain PMH Rheumatoid arthritis 2010 DH Methotrexate Prednisolone 5mg daily (intermittent for flare ups)
4 OP case - lateral thoracic spine xray Can you spot the abnormalities?
5 OP case - lateral thoracic spine xray Vertebral fractures T9 and T12 Wedge fractures
6 >50% are painless Vertebral fractures Xray reports often don t mention the word fracture If vertebral fracture is found, often not investigated for osteoporosis If family history of kyphosis high risk - beware!
7 Classification of vertebral fractures
8 Fragility fractures cause significant morbidity Additional morbidity due to fragility fracture event Morbidity attributable to ageing alone Hip fracture is all too often the final destination of a 30 year journey fuelled by decreasing bone strength and increasing falls risk 2 1. J Endocrinol Invest 1999;30: Kanis JA & Johnell O 2. Osteoporosis Review. 2009;17(1):14-16 Mitchell PJ
9 Osteoporotic vertebral fracture morbidity Signs Kyphosis Loss of height Tummy bulges loss of space below ribs Symptoms Neck pain and head falls forward Back pain Breathing difficulties Indigestion & GO reflux Stress incontinence Poor mobility Falling forwards
10 Differential diagnosis of low trauma Vertebral fractures Exclude bone metastases if: Systemic symptoms GI or respiratory symptoms Neurological symptoms Osteoporosis Consider osteoporosis in anyone age >50 years presenting with a low trauma fracture at any site History of cancer By Requesting: MRI scan or NM bone scan (does not show myeloma though)
11 How do you diagnose osteoporosis?
12 Diagnosis of osteoporosis In the past a DXA scan was the primary investigation Now Fracture Risk Assessment +/- DXA is recommended
13 Components of bone strength Bone turnover Mineralisation BMD Cortical thickness and porosity Bone mineral density (BMD) is only one component of bone strength Geometry Trabecular architecture Healthy Bones/ St George s University Hospitals NHS Foundation Trust Other factors also contribute to bone strength
14 NICE Clinical Guideline 146 Do not routinely measure BMD to assess fracture risk without prior assessment using FRAX or QFracture.
15 Diagnosis of osteoporosis using Fracture Risk Assessment first Clinical Risk factors FRAX fracture probability High Treat Intermediate BMD Reassess probability Low High Low Treat
16 Case history what risk factors for osteoporosis does she have? 66 year old women Presents with new thoracic back pain PMH Rheumatoid arthritis 2010 DH Methotrexate Prednisolone 5mg daily (intermittent for flare ups)
17 Osteoporosis Case Risk factors 66 year old women Presents with new thoracic back pain PMH Rheumatoid arthritis 2010 DH Methotrexate Prednisolone 5mg daily (intermittent for flare ups)
18 Risk factors for osteoporosis Other risk factors: Major risk factors for osteoporotic fracture included in FRAX Untreated premature menopause/hypogonadism Aromatase inhibitor/antiandrogens Primary hyperparathyroidism/cushings/ thyrotoxicosis Liver cirrhosis/severe cholestasis Malabsorption Immobility Previous fragility fracture Glucocorticoids Family history of hip fracture Secondary OP RA Low BMI Smoker High alcohol
19 Osteoporosis case Fracture risk assessment FRAX NOGG Treatment thresholds in UK
20 Limitations of fracture risk assessment tools Some Risk factors not yet included you need to consider them too eg Aromatase inhibitors falls risk not included in FRAX Included in QFRACTURE Risk score applies only to treatment naïve patients BMD input for hip only in FRAX May underestimate risk in those with low spine BMD only
21 Investigations for Osteoporosis Essential in all patients Vit D Bone profile U+E Why? Selected patients Exclude malignancy ESR/myeloma screen/psa Imaging Diagnosing secondary OP PTH TFT LFT Testosterone Coeliac Assessing for asymptomatic fractures if height loss/kyphosis Thoracic/Lumbar spine xrays
22 Treatment of vitamin D deficiency Treatment of severe vitamin D deficiency <30nmol/L loading dose to replenish vitamin D stores first Units weekly for 5 weeks total units Then repeat vitamin D/bone profile 1 month later Then maintenance treatment Treatment of vitamin D insufficiency/maintenance therapy units daily All people age >65 should take vitamin D 400 units daily National Osteoporosis Society vitamin D guidelines 2013
23 Osteoporosis treatments 2 types Antiresorptives reduce osteoclast number/function Anabolics increase Osteoblast activity
24 Osteoporosis Treatment 2 types Antiresorptives Bisphosphonates RANKL inhibitors SERM - Selective Oestrogen Reuptake modulators (Dual action agents Strontium ranelate) (oestrogens if premature menopause) Anabolics Synthetic PTH (Dual action agents - Strontium ranelate)
25 Osteoporosis drugs are highly efficacy Clinical endpoint is low trauma fracture Relative Risk reduction- Vertebral fracture 70% Hip fracture 40% Drug trial efficacy at all sites - hip, spine & major osteoporotic fracture sites Alendronate/Risedronate Denosumab Zoledronate Strontium ranelate
26 1 st Line Treatment Oral bisphosphonates - alendronate Consider switching if: Contraindication to bisphosphonates Intolerant Poor compliance due to eg dementia Treatment failure
27 Oral bisphosphonates- Cautions/Contraindications Oesophageal Severe Indigestion/Strictures/Barretts oesophagus Renal GFR <30 Very poor dentition Exclude metabolic derangement - vit D, Calcium Risk of hypocalcaemia and inefficacy
28 What constitutes 1 st line treatment failure? Patient sustaining a low trauma fracture after >1 year of treatment? Exclude non-adherence and secondary causes Or not? Licensed drugs are not 100% effective Fracture risk reduction: vertebral/hip/non-vertebral 60/40/20%
29 What constitutes 1 st line treatment failure? IOF criteria: 2 or more fragility fractures 1 fragility # + either: significant drop in BMD >4-5%, no significant drop in BTM >20-30% Both significant drop in BMD >4-5% + no significant reduction in BTM Exclude non-adherence and secondary causes Diez-Perez A, Compston JE - Osteoporosis International 2012
30 2 nd line treatment Zoledronate Bisphosphonate annual IV Denosumab - RANKL inhibitor 6 monthly subcut For severe osteoporosis Teriparatide synthetic PTH subcutaneous daily Expensive NICE criteria Less commonly used treatments Raloxifene - SERM mild efficacy Strontium ranelate Dual action agent CVD risk
31 Is Zoledronate more effective than alendronate? Significant reduction in bone turnover markers in zoledronate group
32 2 nd line treatment Zoledronate Bisphosphonate IV Denosumab - RANKL inhibitor subcutaneous For severe osteoporosis Teriparatide synthetic PTH subcutaneous Expensive NICE criteria Less commonly used treatments Raloxifene - SERM mild efficacy Strontium ranelate Dual action agent CVD risk
33 Denosumab RANKL inhibitor
34 Denosumab - Prolia Subcut injection 6 monthly Compliance 100% Community administration Caution GFR < 30ml/min SE infection cellulitis Hypocalcaemia especially if low GFR 34
35 Is Denosumab more effective than alendronate? Switching from alendronate to denosumab leads to: Larger BMD gains More suppression of bone turnover But no fracture data Brown JP, Bone HG 2009 Kendler DL, JBMR 2010
36 Is Denosumab more effective? Meta-analysis 142 RCTs, women* At 3 yrs Denosumab showed greater gains in Lumbar Spine & Total Hip BMD than oral bisphoshonates, zoledronate, raloxifene Teriparatide showed greater gain in Lumbar Spine BMD than denosumab Denosumab better at preventing vertebral # than oral bisphosphonates, strontium ranelate or raloxifene** * Mandema JW, JCEM 2014 **Freemantle N, OI 2013
37 Osteoporosis Practical point Hospital discharge summaries - should include date of giving parenteral treatment and plans for future injections GPs - Include parenteral treatments in patient s usual drug list to prevent duplicate prescribing
38 2 nd line treatment Zoledronate Bisphosphonate IV Denosumab - RANKL inhibitor subcutaneous For severe osteoporosis Teriparatide synthetic PTH subcutaneous Expensive NICE criteria Less commonly used treatments Raloxifene - SERM mild efficacy Strontium ranelate Dual action agent CVD risk
39 Parathyroid hormone peptides eg Teriparatide Efficacy Reduces vertebral and non-vertebral fractures Increases spine BMD more than alendronate 1 Less back pain and improved quality of life 2 Disadvantages Cost Daily subcutaneous injection License limited to 2 years NICE - for 18 mths 1. Body J-J et al J Clin Endocrinol Metab 2002, 87: Crans GC et al Arthritis & Rheumatism Dec Vol 50,12:
40 Saag KG Arthritis Rheumatism 2009
41 Comparison of 3 parenteral drugs Safety Tolerability Additional Denosumab Can increase Infection ONJ Hypocalcaemia (especially in CKD) good Fast onset/offset Consider in CKD Community nurse can give it zoledronate Renal ONJ hypocalcaemia Flu-like symptoms Cheaper Fast onset, slow offset Mortality benefit after hip # License for GIOP teriparatide No ONJ No atypical femoral # Daily injection Fast onset/offset License for GIOP Reduces back pain Increases QoL NICE restricted - expensive Only licensed anabolic drug
42 In practice. Zoledronate is usually given 2 nd line due to cost Unless specific reason to give denosumab instead: Frail/elderly/housebound CKD with GFR around 30 (specialist clinic)
43 Rare side effects of bisphosphonates Atypical femoral fractures Osteonecrosis of the jaw Rare in OP pts <1: Prevention better than cure See Dentist before and during treatment Atypical Femoral fractures Association with bisphosphonates But???causative Rare Prodrome of unusual thigh pain Can be bilateral
44 Management of atypical femoral fractures Stop bisphosphonate Request urgent xray of whole femur Periosteal reaction Insufficiency fracture Consider MRI Xray the other femur Refer to osteoporosis clinic/orthopaedics
45 Bisphosphonates - Risk of atypical fractures vs benefit Treatment with bisphosphonates for 10 yrs: Age adjusted incidence of Atypical femoral fractures = 1.1/1000 pt yrs Non-vertebral fractures prevented = 37 per 1000 pt yrs Vertebral fractures prevented = 62.7 per 1000 pt yrs Black DM, Cummings SR, Karpf DB. Lancet 1996 Ringe JD, Doherty JG. Rheumatol Int 2010 Dell RM, Adams AL, Greene DF. J Bone Miner Res 2012 Liberman UA, Weiss SR, Broll J. N Engl J Med 1995
46 Osteoporosis Case - Treatment Commence alendronate + Adcal D3 Also remember non-drug treatment Analgesia and specialist physiotherapy for vertebral fracture Falls risk assessment Increase protein and BMI if low Specialised osteoporosis exercise program Kyphoplasty/vertebroplasty if severe back pain at 8 weeks
47 Calcium supplements and CVD Increased CVD risk seen in: Bollard MJ 2010 metanalysis calcium alone Bolland MJ 2011 metanalysis Ca/D3 No increased CVD risk seen in: Wang L 2010 metanalysis Lewis J 2013 metanalysis Lewis JR Ancillary of placebo control study Harvey N 2016 Observ Biobank study n= No known mechanism
48 The jury is still out so My advice: Women age <70 yrs on osteoporosis treatment could have vitamin D + dietary calcium Use the calcium calculator
49 But - It is very important that certain patients have Calcium/Vitamin D Low calcium intake/vegans Elderly reduced dietary calcium absorption Glucocorticoid patients Steroids cause a negative calcium balance USA guidelines Ca mg Patients given parenteral antiresorptives Net positive flux of Ca to skeleton Risk of hypocalcaemia if Ca/D3 supplements not given
50 Drug holiday from bisphosphonates Why? Possible risk of long term bone suppression Anti fracture efficacy may persist after stopping bisphosphonates Applies to bisphosphonates with longest skeletal half life zoledronate and alendronate Drug holiday to maintain benefit while reducing the risk Suresh E, Pazianas M, Abrahamsen B. Rheumatol Jan 2014
51 Review patients on bisphosphonates after 5 years (or 3 years for zoledronate) High risk patients continue treatment T<-2.5 hip Previous hip or vertebral fracture Recurrent fractures (consider spine xrays) Ongoing Glucocorticoid treatment Moderate/low risk 2 year drug holiday then reassess T>-2.5 hip and no previous hip or vertebral fractures FDA expert panel McClung M, Harris ST, Miller PD et al. Bisphosphonate therapy for osteoporosis: benefits, risks and drug holiday. Am J Med 2013;126:13 20
52 Denosumab has a fast offset It is not retained in bone beyond 6 months Therefore drug holiday concept does not apply
53 Remember your hospital Fracture Liaison Service (FLS) nurse Identifies all patients age >50y with low trauma (fragility) fractures fracture sustained from a fall from standing height Assessment of osteoporosis risk Osteoporosis treatment initiated
54 Osteoporosis Key learning points 1 Consider osteoporosis in all pts age >50 yrs presenting with fragility fracture Diagnosis of osteoporosis should include fracture risk assessment Don t miss vertebral fractures Osteonecrosis of jaw is rare in osteoporosis patients
55 Osteoporosis Key learning points 2 Fragility fracture despite OP treatment escalate to parenteral treatment Calcium/vitamin D supplements are probably safe regarding cardiovascular disease Review osteoporosis treatment after 5 years and consider drug holiday from bisphosphonates if not high risk
56 Thank you
Osteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationClinical Specialist Statement Template
Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationHow to treat osteoporosis With what and for how long?
How to treat osteoporosis With what and for how long? Professor Neil Gittoes Consultant Endocrinologist & Honorary Professor Where will we be going? Drug therapies Current Indications Contraindications/unmet
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationPathway from Fracture or Risk Factor to Treatment
Appendix 6A - Guidance on Diagnosis and Management of Osteoporosis Pathway from Fracture or Risk Factor to Treatment Fragility Fracture = fracture sustained from a low energy fall from standing height
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationRefracture Prevention The Role of Primary Care
MonashHealth Refracture Prevention The Role of Primary Care Professor Peter R Ebeling AO MBBS MD FRACP Head, Department of Medicine School for Clinical Sciences Monash Health Translation Precinct Monash
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationDumfries and Galloway. Treatment Protocol for Osteoporosis
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 REFERRAL CRITERIA FOR DEXA 3 TREATMENT 4 Non-Drug Therapy : for all 4 Non-Drug Therapy : in the
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationSummary. Background. Diagnosis
March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationDumfries and Galloway. Treatment Protocol for Osteoporosis
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 Multiple low trauma vertebral fractures in the absence of myeloma or metastatic disease. 2 T-score
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationS H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationInitial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above
Initial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above 2 or > vertebral fractures Low trauma fracture In past 5 years Risk Factors (table1)
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE This guideline incorporates some of the recommendations from SIGN, NICE, National Group (NOGG) and local expert opinion. It adopts
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationCase Finding and Risk Assessment for Osteoporosis
Case Finding and Risk Assessment for Osteoporosis Patient may present as a fragility fracture or risk fracture Fragility fracture age 50 Clinical risk factors aged 50 Very strong clinical risk factors
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationBisphosphonate treatment break
Bulletin 110 December 2015 Bisphosphonate treatment break Bisphosphonates have been widely used in the treatment of osteoporosis with robust data demonstrating efficacy in fracture risk reduction over
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.
4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationDiagnosis and management of osteoporosis
Diagnosis and management of osteoporosis Ralston SH, Fraser J. Diagnosis and management of osteoporosis. Practitioner 2015;259 (1788):15-19 Professor Stuart H Ralston MD FRCP Professor of Rheumatology,
More informationPractical Management Of Osteoporosis
Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationRecent advances in the management of osteoporosis
CONFERENCE SUMMARIES Clinical Medicine 2009, Vol 9, No 6: 565 9 Recent advances in the management of osteoporosis Juliet Compston Introduction Osteoporotic fractures are a major cause of morbidity and
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationFRAX assessment. The patient. The patient. Which drug? UK NOGG Guidance 3/22/17. Safety issues with osteoporosis treatments
The patient Safety issues with osteoporosis treatments 78 year-old lady, retired dentist, active. Family history of osteoporosis (mother, younger sister). Humerus fracture 3 months ago. Type 2 diabetes
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationNICE SCOOP OF THE DAY FRAX with NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield
NICE SCOOP OF THE DAY FRAX with NOGG Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield Disclosures Consultant/Advisor/Speaker for: o ActiveSignal, Amgen, AstraZeneca, Consilient
More informationOsteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017
Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1
More informationAssessment and management of glucocorticoid-induced osteoporosis
PRESCRIBING IN PRACTICE n Assessment and management of glucocorticoid-induced osteoporosis Gerald Tracey and Tehseen Ahmed Glucocorticoid-induced osteoporosis (GIO) is the most prevalent form of secondary
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationHot Topics in Osteoporosis and Fracture Prevention
Hot Topics in Osteoporosis and Fracture Prevention Sid Feldman, MD CCFP (COE) FCFP Sandra Kim, MD, FRCPC November 15, 2018 Family Medicine Forum, Toronto Faculty/Presenter Disclosure Faculty: Sid Feldman
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationFRAX, NICE and NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield
FRAX, NICE and NOGG Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield Disclosures Research funding and/or honoraria and/or advisory boards for: o ActiveSignal, Amgen, Bayer, Boehringer
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
: assessing the risk of fragility fracture bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Appendix I - Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationPage 1
Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationMPharm Programme. Osteoporosis in Practice (L4) Louise Statham- Senior Lecturer in Clinical Pharmacy
MPharm Programme Osteoporosis in Practice (L4) Louise Statham- Senior Lecturer in Clinical Pharmacy Louise.statham@sunderland.ac.uk Slide 1 of 47 MPHM13 Module Introduction Aims This lecture will build
More informationClinical Practice. Presented by: Internist, Endocrinologist
Clinical Practice Management of Osteoporosis Presented by: SaeedBehradmanesh, h MD Internist, Endocrinologist Iran, Isfahan, Feb. 2017 Definition: A disease characterized by low bone mass and microarchitectural
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationBisphosphonates Length of treatment in osteoporosis in primary care- Treatment holiday
Bisphosphonates Length of treatment in osteoporosis in primary care- Treatment holiday This guidance incorporate National Osteoporosis Guideline Group (NOGG) guidance March 2017 Clinical guideline for
More informationDENOSUMAB SHARED CARE GUIDLINES
DENOSUMAB LICENSING Denosumab (PROLIA ) is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for bone loss associated with hormone ablation in men with
More informationHot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationACP Colorado-Evidence Based Management of Osteoporosis
ACP Colorado-Evidence Based Management of Osteoporosis Micol S. Rothman, MD Associate Professor of Medicine and Radiology Clinical Director Metabolic Bone Program University of Colorado School of Medicine
More information